CN1569100A - Medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method - Google Patents
Medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method Download PDFInfo
- Publication number
- CN1569100A CN1569100A CNA2003101159784A CN200310115978A CN1569100A CN 1569100 A CN1569100 A CN 1569100A CN A2003101159784 A CNA2003101159784 A CN A2003101159784A CN 200310115978 A CN200310115978 A CN 200310115978A CN 1569100 A CN1569100 A CN 1569100A
- Authority
- CN
- China
- Prior art keywords
- parts
- dry extract
- radix
- medicine
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 206010002556 Ankylosing Spondylitis Diseases 0.000 title claims abstract description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title claims description 12
- 241000218176 Corydalis Species 0.000 claims abstract description 17
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 17
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 56
- 239000000843 powder Substances 0.000 claims description 32
- 241000255791 Bombyx Species 0.000 claims description 18
- 241000272074 Bungarus Species 0.000 claims description 18
- 241001550206 Colla Species 0.000 claims description 18
- 241000209020 Cornus Species 0.000 claims description 18
- 241001489978 Eupolyphaga Species 0.000 claims description 18
- 241000237636 Pheretima Species 0.000 claims description 18
- 241000131808 Scolopendra Species 0.000 claims description 18
- 241000522620 Scorpio Species 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 241000283956 Manis Species 0.000 claims description 16
- 239000009286 sanguis draxonis Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000009490 scorpio Substances 0.000 claims description 13
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000489492 Arisaema Species 0.000 abstract 1
- 241000255789 Bombyx mori Species 0.000 abstract 1
- 241000282994 Cervidae Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 241000272060 Elapidae Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241001481692 Mesobuthus martensii Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 241000270295 Serpentes Species 0.000 abstract 1
- 240000004824 Trimezia steyermarkii Species 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000009136 dragon's blood Substances 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 235000020061 kirsch Nutrition 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 208000006820 Arthralgia Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000000552 rheumatic effect Effects 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 241000271039 Agkistrodon Species 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 210000000504 visceral peritoneum Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 208000008822 Ankylosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000010555 moderate anemia Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010048628 rheumatoid vasculitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003131 sacroiliac joint Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Abstract
The invention provides a medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method, wherein the preparation is prepared form Chinese medicinal herbs incluing multibanded krait, black-tail snake, earthworm, buthus martensi kirsch, centipede, pangolin scales, American ginseng, dragon's blood resin, notoginseng, wood louse, batryticated silkworm, apiary, deer horn gum, root of herbaceous peony, arisaema tuber, corydalis tuber, licorice root, and borneol.
Description
Technical field:
The present invention relates to a kind of Chinese medicine, especially relate to a kind of pure Chinese medicinal preparation for the treatment of rheumatoid arthritis, ankylosing spondylitis and preparation method thereof.
Background technology:
Rheumatoid arthritis is a kind of chronic general immunity disease, is more common in person between twenty and fifty.It shows as arthroncus, pain, stiff in early days, can cause that ankylosis, deformity and function are badly damaged late period, in addition can be with showing outside the joints such as low grade fever, anemia, General Symptoms and rheumatoid knot inflammation such as lose weight, rheumatoid vasculitis, cardiopulmonary kidney be impaired.From morbidity, primary disease betides all over the world.Add up according to foreign data, sickness rate is about 1.0%, domestic Beijing and Guangdong area population is investigated, its sickness rate is about 0.3%-0.5%, recently, by with the cooperation investigation of international wind resistance damp disease alliance, the sickness rate of determining China's rheumatoid arthritis is 0.3%, nearly about 5,000,000 the rheumatoid patient in the whole nation, as seen this disease is not rare; Ankylosing spondylitis is a kind of main infringement spinal column, and the accumulation sacroiliac joint that can be in various degree and the chronic progressive external inflammatory diseases in joint on every side, and by the preliminary survey to this province population, its sickness rate is 0.5 ‰-0.7 ‰.This shows that traditional Chinese medical science arthromyodynias such as rheumatoid arthritis and ankylosing spondylitis can have a strong impact on human quality of life, bring heavier burden for family and society, so its study on prevention has become one of problem of World Health Organization's research.At present, domestic and international treatment for rheumatic arthritis and ankylosing spondylitis rests on the Western medicine bases such as non-steroidal drug, antigout drug and steroidal class anti inflammatory immunity medicine mostly.Because the toxic and side effects and the range of application of this class Western medicine are limit, thereby make rheumatoid arthritis, ankylosing spondylitis not be effectively controlled.Facts have proved, motherland's medicine and pharmacology are accumulating rich experience aspect treatment rheumatoid arthritis, the ankylosing spondylitis disease, the traditional Chinese medical science is more emphasized whole treatment, treating both the principal and secondary aspects of a disease puts prevention first, Chinese medicine is few and celebrated with untoward reaction, therefore, a kind of this sick new medicine compound preparation for the treatment of of development is highly significant with necessity.
Summary of the invention:
Technical problem to be solved by this invention provides pure Chinese medicinal preparation that a kind of curative effect for the treatment of rheumatoid arthritis, ankylosing spondylitis gives prominence to, has no side effect and preparation method thereof.
Medicine of the present invention is mixed and made into by weight by following bulk drugs:
Bungarus Parvus 2-20 part Zaocys 30-70 part Pheretima 20-50 part
Scorpio 20-50 part Scolopendra 20-50 part Squama Manis 20-50 part
Radix Panacis Quinquefolii 20-50 part Sanguis Draxonis 20-50 part Radix Notoginseng 10-40 part
Eupolyphaga Seu Steleophaga 10-40 part Bombyx Batryticatus 10-40 part Nidus Vespae 5-20 part
Colla cornus cervi 20-30 part Radix Paeoniae Alba 50-100 part Rhizoma Arisaematis (processed) 30-70 part
Rhizoma Corydalis 20-50 part Radix Glycyrrhizae 5-20 part Borneolum Syntheticum 1-10 part
Its preparation method is:
A) Bungarus Parvus, Pheretima, Scorpio, Scolopendra, Squama Manis, Radix Panacis Quinquefolii, Sanguis Draxonis, Radix Notoginseng, the Colla cornus cervi with described weight proportion is ground into fine powder 1 after mixing;
B) Rhizoma Corydalis of described weight proportion being added concentration is that the ethanol of 50%-80% carries out reflux, extract,, is condensed into the dry extract 1 of relative density 1-2;
C) Zaocys, Eupolyphaga Seu Steleophaga, Bombyx Batryticatus, Nidus Vespae, the Radix Paeoniae Alba, Rhizoma Arisaematis (processed), the Radix Glycyrrhizae with described weight proportion decocts with water 2-6 time, and each amount of water was not advisable to have powder, collecting decoction, filtration, and being condensed into proportion is the dry extract 2 of 1-2;
D) merge dry extract 1 and dry extract 2, continue to concentrate, get dry extract 3;
E) merge dry extract 3 and fine powder 1, be ground into fine powder again, promptly get the active component of medicine of the present invention.
The present invention selects the deep wind of searching of Bungarus Parvus for use, promoting the flow of QI-blood by warming the meridian, and numbness is exempted from dehumidifying, " Kaibao Bencao " said: " main apoplexy arthralgia chiefly caused by damp pathogen is meciless, spasm of muscles and vessels ", the nearly Agkistrodon of Zaocys and unable slow nontoxic, especially be longer than the wind of the muscle skin of dispelling, " Kaibao Bencao " said: " munbness, all wind of insensitive impediment ".So is principal agent with two Serpentiss, can in walk visceral peritoneum, reach skin outward, be the key medicine of treatment rheumatic arthralgia.Minister Scorpio, Scolopendra removing obstruction in the collateral to relieve pain, dispersing pathogen accumulation, mutual reinforcement between is a usefulness, and effect all increases, and " ginseng west record in the inner feelings " said: " all QI and blood cohesion parts all can be opened it ".To rheumatic arthralgia etc., to take out the pain person that pulls for good especially.The pain relieving that relieves dizziness, high fever, infantile convulsions, epilepsy, etc. of Bombyx Batryticatus, Pheretima, detoxicating and resolving stagnation of pathogens, two medicines mutually 5 with going into Liver Channel (liver governing tendons), is used to unfold grain, is for good right.Nidus Vespae, Rhizoma Arisaematis (processed) dispelling pathogenic wind and eliminating phlegm, dispersing swelling and dissipating binds is searched the damp-phlegm stream that picks the joint and is stayed.Stir-baked SQUAMA MANITIS, Eupolyphaga Seu Steleophaga blood circulation promoting and blood stasis dispelling, subduing swelling and relieving pain can be dismissed QI and blood and be stirred thorn, and interior blood trouble is poly-.All medicines are auxilliary mutually, not only can strengthen expelling wind and cold, and the effect of removing damp and stopping pain, and promoting circulation of QI-blood make the QI and blood smoothness, and the resistance of general rule numbness is opened and not bitterly, and accord with the reason of " control wind and control blood, blood sector-style earlier from going out ".Assistant is with Radix Panacis Quinquefolii QI invigorating tonifying YIN, and is warm and not dry, do not have the suspicion of lighting a fire, and is beneficial to long clothes; The Colla cornus cervi enriching blood and replenishing vital essence, warm strengthening bone and muscle; The Radix Paeoniae Alba yin fluid astringing that nourishes blood, easing the affected liver to relieve pain, three's assistant helps the warm blood of gas to moisten, and strong muscles and bones can make heresy go and the stay-at-home nothing of healthy energy is hindered, and is perfectly sound with plan.Make with the invigorating middle warmer of Radix Glycyrrhizae QI invigorating, coordinating the actions of various ingredients in a prescription is played expelling cold and dampness altogether, the effect of removing obstruction in the collateral to relieve pain.
The active component of medicine of the present invention can add preparation required various conventional adjuvant during different dosage form, is prepared into any peroral dosage form commonly used with the method for Chinese medicinal of routine, as granule, powder, tablet, capsule, oral liquid etc.
The deep wind of searching of Bungarus Parvus among the present invention, promoting the flow of QI-blood by warming the meridian, numbness is exempted from dehumidifying, " Kaibao Bencao " said: " main apoplexy arthralgia chiefly caused by damp pathogen is meciless, spasm of muscles and vessels ", the nearly Agkistrodon of Zaocys and unable slow nontoxic, especially be longer than the wind of the muscle skin of dispelling, " Kaibao Bencao " said: " munbness, all wind of insensitive impediment ".So is principal agent with two Serpentiss, can in walk visceral peritoneum, reach skin outward, be the key medicine of treatment rheumatic arthralgia.Minister Scorpio, Scolopendra removing obstruction in the collateral to relieve pain, dispersing pathogen accumulation, mutual reinforcement between is a usefulness, and effect all increases, and " ginseng west record in the inner feelings " said: " all QI and blood cohesion parts all can be opened it ".To rheumatic arthralgia etc., to take out the pain person that pulls for good especially.The pain relieving that relieves dizziness, high fever, infantile convulsions, epilepsy, etc. of Bombyx Batryticatus, Pheretima, detoxicating and resolving stagnation of pathogens, two medicines mutually 5 with going into Liver Channel (liver governing tendons), is used to unfold grain, is for good right.Nidus Vespae, Rhizoma Arisaematis (processed) dispelling pathogenic wind and eliminating phlegm, dispersing swelling and dissipating binds is searched the damp-phlegm stream that picks the joint and is stayed.Stir-baked SQUAMA MANITIS, Eupolyphaga Seu Steleophaga blood circulation promoting and blood stasis dispelling, subduing swelling and relieving pain can be dismissed QI and blood and be stirred thorn, and interior blood trouble is poly-.All medicines are auxilliary mutually, not only can strengthen expelling wind and cold, and the effect of removing damp and stopping pain, and promoting circulation of QI-blood make the QI and blood smoothness, and the resistance of general rule numbness is opened and not bitterly, and accord with the reason of " control wind and control blood, blood sector-style earlier from going out ".Assistant is with Radix Panacis Quinquefolii QI invigorating tonifying YIN, and is warm and not dry, do not have the suspicion of lighting a fire,, be beneficial to long clothes; The Colla cornus cervi enriching blood and replenishing vital essence, warm strengthening bone and muscle; The Radix Paeoniae Alba yin fluid astringing that nourishes blood, easing the affected liver to relieve pain, three's assistant helps the warm blood of gas to moisten, and strong muscles and bones can make heresy go and the stay-at-home nothing of healthy energy is hindered, and is perfectly sound with plan.Make with the invigorating middle warmer of Radix Glycyrrhizae QI invigorating, coordinating the actions of various ingredients in a prescription is played expelling cold and dampness altogether, the effect of removing obstruction in the collateral to relieve pain.
The present invention is according to the characteristics of rheumatoid arthritis, the ankylosing spondylitis tool traditional Chinese medical science " insensitive impediment " disease, at its cause of disease, innovation utilization main body, object double treatment are safeguarded human body dynamic equilibrium, to reach the Therapeutic Principle of dispelling cold and removing dampness, removing obstruction in the collateral to relieve pain on treatment mechanism; Advanced technologies such as adoption of innovation dynamic extraction, concentrating under reduced pressure, spray drying on the production technology; Quality standard advanced person, controlled; Efficacy is clear and definite, and curative effect is outstanding, and is safe and reliable, has no side effect.
The specific embodiment:
Below further set forth the beneficial effect of medicine of the present invention by testing example, these are tested examples and have comprised that the pharmacodynamics test of medicine of the present invention (disappearing to call insensitive impediment in the following text) and clinical observation on the therapeutic effect test.
[test example 1]
Test method: the Wistar rat is divided into four groups at random by body weight, sex, 30 every group, gastric infusion.
1) to the treatment of experimental arthritis
Annotate :+for treating the degree that takes a turn for the better
Conclusion: by the rat assist agent arthritis experiment, insensitive impediment disappears, and former phase, the foot swelling of secondary phase have obvious inhibitory action to rat assist agent arthritis, and infringements such as ear's erythema of administration group rat and afterbody tuberosity all obviously alleviate than matched group FENGSHIBIKANG JIAONANG.In whole experiment, do not see the obviously variation of minimizing and mode of appearance etc. of animal ingestion.
2) to Immune Effects
| Group, dosage (mg/kg) | Number of animals | The K value | The A value |
| ??360 | 10 | ????0.0402±0.0100 | ????6.06±0.68 |
| ??180 | 10 | ????0.0320±0.0090 | ????5.69±0.51 |
| ??90 | 10 | ????0.0300±0.0076 | ????5.69±0.52 |
| Positive drug 9750 | 10 | ????0.0440±0.0139 | ????6.18±0.86 |
| Matched group | 10 | ????0.0286±0.0121 | ????5.62±0.97 |
By the experiment of DNCB induced mice skin of pinna delayed hypersensitivity, insensitive impediment disappears has obvious inhibitory action to delayed hypersensitivity due to the DNCB; By the experiment to the Turnover of Mouse Peritoneal Macrophages phagocytic function, the insensitive impediment capsule for eliminating has significant facilitation to the Turnover of Mouse Peritoneal Macrophages phagocytic function; By the experiment to hemolysin content in the mice serum, the insensitive impediment capsule for eliminating can significantly improve hemolysin content in the mice serum.
3) antiinflammatory action
Influence to rat granuloma hamartoplasia
| Group, dosage (mg/kg) | Number of animals | Granuloma induced by implantation of cotton pellets weight | Suppression ratio (%) |
| ???250 | 10 | ????31.1±8.63 | ????28.67 |
| ???125 | 10 | ????32.2±9.52 | ????26.15 |
| ???62.5 | 10 | ????32.9±10.66 | ????24.54 |
| Hydrocortisone 200 | 10 | ????26.2±6.44 | ????39.91 |
| Contrast | 10 | ????43.6±8.12 |
By the experiment of rat carrageenan foot swelling, insensitive impediment disappears, and foot swelling has obvious inhibitory action to rat carrageenan; By the experiment of rat granuloma hamartoplasia, insensitive impediment disappears and can obviously reduce granulation tissue weight, and the effect of obvious inhibition cott on pellet-induced granuloma formation is arranged; By the experiment of mouse peritoneal capillary permeability, the abdominal cavity capillary permeability of insensitive impediment capsule for eliminating Dichlorodiphenyl Acetate induced mice strengthens the obvious suppression effect.
4) analgesic activity
| Group, dosage (mg/kg) | Number of animals | Turn round the body number of times |
| ???360 | 10 | ????20.1±3.84 |
| ???180 | 10 | ????24.7±3.83 |
| ???90 | 10 | ????24.0±3.77 |
| Aspirin 200 | 10 | ????18.1±6.01 |
| Matched group | 10 | ????25.0±4.03 |
By the experiment of hot plate induced mice pain reaction, insensitive impediment disappears and can obviously prolong the incubation period of hot plate induced mice pain reaction, and obvious analgesic activity is arranged; By the experiment of acetic acid induced mice writhing response, insensitive impediment disappear can obviously reduce acetic acid induced mice abdominal cavity pain turn round the body number of times, obvious analgesic activity is arranged.
Above-mentioned experimentation all adopts FENGSHIBIKANG JIAONANG to do matched group, and the most pharmacological actions of insensitive impediment capsule for eliminating are better than FENGSHIBIKANG JIAONANG.
[test example 2]
It is for many years clinical that medicine insensitive impediment of the present invention disappears, and application process is evident in efficacy, and concrete clinical observation sees the following form:
| Check index | The example number | Index classification before the treatment | The index classification of treatment back | ||||||
| ????0 | ????I | ????II | ????III | ????0 | ????I | ????II | ????III | ||
| Deadlock in morning (h) | 400 | ????6 | ????71 | ????139 | ????184 | ????204 | ????130 | ????61 | ????5 |
| The arthralgia index | 400 | ????0 | ????73 | ????144 | ????183 | ????162 | ????156 | ????74 | ????3 |
| Joint swelling index | 400 | ????4 | ????63 | ????176 | ????152 | ????161 | ????132 | ????69 | ????18 |
| The joint movement disorder index | 400 | ????27 | ????58 | ????137 | ????178 | ????112 | ????169 | ????98 | ????21 |
| Rheumatoid factor | 400 | Positive 152 examples of the 273 examples negative conversion rate 55.8% of turning out cloudy | |||||||
| Erythrocyte sedimentation rate | 400 | 30mm/h rate of descent 82.2% on average falls in 297 examples 〉=normal 173 examples of 20mm/h 80 examples | |||||||
| Anti-" O " | 400 | 152 examples＞example was recovered normal or rate of descent 82.2% in 1: 500 125 | |||||||
| Hemoglobin | 400 | Light moderate anemia 208 examples of 242 examples are recovered normal or are improved improvement rate 85.9% | |||||||
| Leukocyte | 400 | Light moderate rising 196 examples of 203 examples are recovered normal or are improved improvement rate 96.5% | |||||||
Conclusion: 98% patient's clinical symptoms is improved, and 85% patient's lab index is improved, and 55.8% patient RF turns out cloudy, and red, leukocyte and hepatic and renal function are had no adverse effects, and insensitive impediment capsule for eliminating group cure-remarkable-effectiveness rate and total effective rate are apparently higher than the indometacin group.
Embodiment 1
Take by weighing raw material by following weight portion:
30 parts of 2 parts of Zaocyss of Bungarus Parvus
20 parts of 20 portions of Scorpios of Pheretima
20 parts of 20 parts of Squama Maniss of Scolopendra
20 parts of 20 parts of Sanguis Draxonis of Radix Panacis Quinquefolii
10 parts of 10 parts of Eupolyphaga Seu Steleophagas of Radix Notoginseng
5 parts in 10 parts of Nidus Vespae of Bombyx Batryticatus
50 parts of 10 portions of Radix Paeoniae Albas of Colla cornus cervi
20 parts of 30 parts of Rhizoma Corydalis of Rhizoma Arisaematis (processed)
1 part of 5 parts of Borneolum Syntheticum of Radix Glycyrrhizae
A) Bungarus Parvus, Pheretima, Scorpio, Scolopendra, Squama Manis, Radix Panacis Quinquefolii, Sanguis Draxonis, Radix Notoginseng, the Colla cornus cervi with described weight proportion is ground into fine powder 1 after mixing;
B) Rhizoma Corydalis of described weight proportion being added concentration is that 65% ethanol carries out reflux, extract,, is condensed into the dry extract 1 of relative density 1.33;
C) Zaocys, Eupolyphaga Seu Steleophaga, Bombyx Batryticatus, Nidus Vespae, the Radix Paeoniae Alba, Rhizoma Arisaematis (processed), the Radix Glycyrrhizae with described weight proportion decocts with water 3 times, and each amount of water was not advisable to have powder, and collecting decoction, filtration are condensed into proportion and are 1.33 dry extract 2;
D) merge dry extract 1 and dry extract 2, continue to concentrate, get dry extract 3;
E) merge dry extract 3 and fine powder 1, be ground into fine powder again, can obtain the active component of medicine of the present invention.
Embodiment 2
Take by weighing raw material by following weight portion:
35 parts of 15 parts of Radix Panacis Quinquefoliis of Bungarus Parvus
25 parts of 35 portions of Radix Notoginseng of Pheretima
25 parts of 35 parts of Bombyx Batryticatus of Scolopendra
35 parts of 25 parts of Sanguis Draxonis of Colla cornus cervi
25 parts of 45 parts of Eupolyphaga Seu Steleophagas of Rhizoma Arisaematis (processed)
15 parts in 15 parts of Nidus Vespae of Radix Glycyrrhizae
55 parts of 55 portions of Radix Paeoniae Albas of Zaocys
35 parts of 35 parts of Rhizoma Corydalis of Scorpio
3 parts of 35 parts of Borneolum Syntheticums of Squama Manis
A) Bungarus Parvus, Pheretima, Scorpio, Scolopendra, Squama Manis, Radix Panacis Quinquefolii, Sanguis Draxonis, Radix Notoginseng, the Colla cornus cervi with described weight proportion is ground into fine powder 1 after mixing;
B) Rhizoma Corydalis of described weight proportion being added concentration is that 70% ethanol carries out reflux, extract,, is condensed into the dry extract 1 of relative density 1.33;
C) Zaocys, Eupolyphaga Seu Steleophaga, Bombyx Batryticatus, Nidus Vespae, the Radix Paeoniae Alba, Rhizoma Arisaematis (processed), the Radix Glycyrrhizae with described weight proportion decocts with water 3 times, and each amount of water was not advisable to have powder, and collecting decoction, filtration are condensed into proportion and are 1.33 dry extract 2;
D) merge dry extract 1 and dry extract 2, continue to concentrate, get dry extract 3;
E) merge dry extract 3 and fine powder 1, be ground into fine powder again, promptly get the active component of medicine of the present invention.
Embodiment 3
Take by weighing raw material by following weight portion:
70 parts of 20 parts of Zaocyss of Bungarus Parvus
50 parts of 50 portions of Scorpios of Pheretima
50 parts of 50 parts of Squama Maniss of Scolopendra
50 parts of 50 parts of Sanguis Draxonis of Radix Panacis Quinquefolii
40 parts of 40 parts of Eupolyphaga Seu Steleophagas of Radix Notoginseng
20 parts in 40 parts of Nidus Vespae of Bombyx Batryticatus
100 parts of 40 portions of Radix Paeoniae Albas of Colla cornus cervi
50 parts of 70 parts of Rhizoma Corydalis of Rhizoma Arisaematis (processed)
10 parts of 20 parts of Borneolum Syntheticums of Radix Glycyrrhizae
A) Bungarus Parvus, Pheretima, Scorpio, Scolopendra, Squama Manis, Radix Panacis Quinquefolii, Sanguis Draxonis, Radix Notoginseng, the Colla cornus cervi with described weight proportion is ground into fine powder 1 after mixing;
B) Rhizoma Corydalis of described weight proportion being added concentration is that 75% ethanol carries out reflux, extract,, is condensed into the dry extract 1 of relative density 1.33;
C) Zaocys, Eupolyphaga Seu Steleophaga, Bombyx Batryticatus, Nidus Vespae, the Radix Paeoniae Alba, Rhizoma Arisaematis (processed), the Radix Glycyrrhizae with described weight proportion decocts with water 3 times, and each amount of water was not advisable to have powder, and collecting decoction, filtration are condensed into proportion and are 1.33 dry extract 2;
D) merge dry extract 1 and dry extract 2, continue to concentrate, get dry extract 3;
E) merge dry extract 3 and fine powder 1, be ground into fine powder again, promptly get the active component of medicine of the present invention.
The capsule preparation of embodiment 4 medicines of the present invention
Take by weighing raw material by following weight portion:
55 parts of 15 parts of Zaocyss of Bungarus Parvus
35 parts of 35 portions of Scorpios of Pheretima
35 parts of 35 parts of Squama Maniss of Scolopendra
35 parts of 35 parts of Sanguis Draxonis of Radix Panacis Quinquefolii
25 parts of 25 parts of Eupolyphaga Seu Steleophagas of Radix Notoginseng
15 parts in 25 parts of Nidus Vespae of Bombyx Batryticatus
55 parts of 25 portions of Radix Paeoniae Albas of Colla cornus cervi
35 parts of 45 parts of Rhizoma Corydalis of Rhizoma Arisaematis (processed)
3 parts of 15 parts of Borneolum Syntheticums of Radix Glycyrrhizae
A) Bungarus Parvus, Pheretima, Scorpio, Scolopendra, Squama Manis, Radix Panacis Quinquefolii, Sanguis Draxonis, Radix Notoginseng, the Colla cornus cervi with described weight proportion is ground into fine powder 1 after mixing;
B) Rhizoma Corydalis of described weight proportion being added concentration is that 75% ethanol carries out reflux, extract,, is condensed into the dry extract 1 of relative density 1.33;
C) Zaocys, Eupolyphaga Seu Steleophaga, Bombyx Batryticatus, Nidus Vespae, the Radix Paeoniae Alba, Rhizoma Arisaematis (processed), the Radix Glycyrrhizae with described weight proportion decocts with water 3 times, and each amount of water was not advisable to have powder, and collecting decoction, filtration are condensed into proportion and are 1.33 dry extract 2;
D) merge dry extract 1 and dry extract 2, continue to concentrate, get dry extract 3;
E) merge dry extract 3 and fine powder 1, be ground into fine powder again, make granule, incapsulate, promptly.
The preparation of embodiment 5 medicinal tablets of the present invention
Take by weighing raw material by following weight portion:
30 parts of 5 parts of Zaocyss of Bungarus Parvus
25 parts of 25 portions of Scorpios of Pheretima
25 parts of 25 parts of Squama Maniss of Scolopendra
25 parts of 25 parts of Sanguis Draxonis of Radix Panacis Quinquefolii
15 parts of 15 parts of Eupolyphaga Seu Steleophagas of Radix Notoginseng
10 parts in 15 parts of Nidus Vespae of Bombyx Batryticatus
60 parts of 15 portions of Radix Paeoniae Albas of Colla cornus cervi
25 parts of 30 parts of Rhizoma Corydalis of Rhizoma Arisaematis (processed)
10 parts of 10 parts of Borneolum Syntheticums of Radix Glycyrrhizae
A) Bungarus Parvus, Pheretima, Scorpio, Scolopendra, Squama Manis, Radix Panacis Quinquefolii, Sanguis Draxonis, Radix Notoginseng, the Colla cornus cervi with described weight proportion is ground into fine powder 1 after mixing;
B) Rhizoma Corydalis of described weight proportion being added concentration is that 75% ethanol carries out reflux, extract,, is condensed into the dry extract 1 of relative density 1.33;
C) Zaocys, Eupolyphaga Seu Steleophaga, Bombyx Batryticatus, Nidus Vespae, the Radix Paeoniae Alba, Rhizoma Arisaematis (processed), the Radix Glycyrrhizae with described weight proportion decocts with water 3 times, and each amount of water was not advisable to have powder, and collecting decoction, filtration are condensed into proportion and are 1.33 dry extract 2;
D) merge dry extract 1 and dry extract 2, continue to concentrate, get dry extract 3;
E) merge dry extract 3 and fine powder 1, be ground into fine powder again, make granule, dry, tabletting promptly get tablet of the present invention.
The preparation of embodiment 6 medicinal granules of the present invention
Take by weighing raw material by following formula ratio:
50 parts of 3 parts of Zaocyss of Bungarus Parvus
45 parts of 45 portions of Scorpios of Pheretima
45 parts of 45 parts of Squama Maniss of Scolopendra
45 parts of 45 parts of Sanguis Draxonis of Radix Panacis Quinquefolii
25 parts of 25 parts of Eupolyphaga Seu Steleophagas of Radix Notoginseng
14 parts in 25 parts of Nidus Vespae of Bombyx Batryticatus
65 parts of 25 portions of Radix Paeoniae Albas of Colla cornus cervi
45 parts of 50 parts of Rhizoma Corydalis of Rhizoma Arisaematis (processed)
9 parts of 14 parts of Borneolum Syntheticums of Radix Glycyrrhizae
A) Bungarus Parvus, Pheretima, Scorpio, Scolopendra, Squama Manis, Radix Panacis Quinquefolii, Sanguis Draxonis, Radix Notoginseng, the Colla cornus cervi with described weight proportion is ground into fine powder 1 after mixing;
B) Rhizoma Corydalis of described weight proportion being added concentration is that 75% ethanol carries out reflux, extract,, is condensed into the dry extract 1 of relative density 1.33;
C) Zaocys, Eupolyphaga Seu Steleophaga, Bombyx Batryticatus, Nidus Vespae, the Radix Paeoniae Alba, Rhizoma Arisaematis (processed), the Radix Glycyrrhizae with described weight proportion decocts with water 3 times, and each amount of water was not advisable to have powder, and collecting decoction, filtration are condensed into proportion and are 1.33 dry extract 2;
D) merge dry extract 1 and dry extract 2, continue to concentrate, get dry extract 3;
E) merge dry extract 3 and fine powder 1, add sucrose and dextrin, make granule, drying, promptly.
Claims (2)
1, a kind of medicine for the treatment of rheumatoid arthritis, ankylosing spondylitis is characterized in that: it is to be made by following bulk drugs:
Bungarus Parvus 2-20 part Zaocys 30-70 part Pheretima 20-50 part
Scorpio 20-50 part Scolopendra 20-50 part Squama Manis 20-50 part
Radix Panacis Quinquefolii 20-50 part Sanguis Draxonis 20-50 part Radix Notoginseng 10-40 part
Eupolyphaga Seu Steleophaga 10-40 part Bombyx Batryticatus 10-40 part Nidus Vespae 5-20 part
Colla cornus cervi 20-30 part Radix Paeoniae Alba 50-100 part Rhizoma Arisaematis (processed) 30-70 part
Rhizoma Corydalis 20-50 part Radix Glycyrrhizae 5-20 part Borneolum Syntheticum 1-10 part.
2, the preparation method of the described medicine of claim 1, it comprises the following steps:
A) take by weighing each crude drug, standby;
B) Bungarus Parvus, Pheretima, Scorpio, Scolopendra, Squama Manis, Radix Panacis Quinquefolii, Sanguis Draxonis, Radix Notoginseng, the Colla cornus cervi with described weight proportion is ground into fine powder 1 after mixing;
C) Rhizoma Corydalis of described weight proportion being added concentration is that the ethanol of 50%-80% carries out reflux, extract,, is condensed into the dry extract 1 of relative density 1-2;
D) Zaocys, Eupolyphaga Seu Steleophaga, Bombyx Batryticatus, Nidus Vespae, the Radix Paeoniae Alba, Rhizoma Arisaematis (processed), the Radix Glycyrrhizae with described weight proportion decocts with water 2-6 time, and each amount of water was not advisable to have powder, collecting decoction, filtration, and being condensed into proportion is the dry extract 2 of 1-2;
E) merge dry extract 1 and dry extract 2, continue to concentrate, get dry extract 3;
F) merge dry extract 3 and fine powder 1, be ground into fine powder again, promptly get the active component of medicine of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101159784A CN1286495C (en) | 2003-12-26 | 2003-12-26 | Medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101159784A CN1286495C (en) | 2003-12-26 | 2003-12-26 | Medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1569100A true CN1569100A (en) | 2005-01-26 |
| CN1286495C CN1286495C (en) | 2006-11-29 |
Family
ID=34473905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101159784A Expired - Lifetime CN1286495C (en) | 2003-12-26 | 2003-12-26 | Medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1286495C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100418573C (en) * | 2005-11-30 | 2008-09-17 | 辽宁中医学院附属医院 | External Chinese medicine for treating ankylosing spondylitis |
| CN102600404A (en) * | 2012-03-28 | 2012-07-25 | 裴晶 | Traditional Chinese medicine for treating undifferentiated spondyloarthropathy |
| CN101190267B (en) * | 2006-11-20 | 2012-08-29 | 舒财 | Medicinal composition for treating cervical vertebra disease |
| CN102836299A (en) * | 2012-09-28 | 2012-12-26 | 郑州中医骨伤病医院 | Kidney tonifying and pain relieving pill for treating ankylosing spondylitis |
| CN102847074A (en) * | 2012-09-28 | 2013-01-02 | 郑州中医骨伤病医院 | Blood stasis removing pill for treating ankylosing spondylitis |
| CN103272064A (en) * | 2013-06-17 | 2013-09-04 | 贵州鸿德中药开发有限公司 | Traditional Chinese medicine for treating rheumatoid arthritis and preparation method of traditional Chinese medicine |
| CN104644931A (en) * | 2015-01-29 | 2015-05-27 | 张爱文 | Traditional Chinese medicine for treating phlegm-dampness stagnation type knee joint wound synovitis |
-
2003
- 2003-12-26 CN CNB2003101159784A patent/CN1286495C/en not_active Expired - Lifetime
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100418573C (en) * | 2005-11-30 | 2008-09-17 | 辽宁中医学院附属医院 | External Chinese medicine for treating ankylosing spondylitis |
| CN101190267B (en) * | 2006-11-20 | 2012-08-29 | 舒财 | Medicinal composition for treating cervical vertebra disease |
| CN102600404A (en) * | 2012-03-28 | 2012-07-25 | 裴晶 | Traditional Chinese medicine for treating undifferentiated spondyloarthropathy |
| CN102600404B (en) * | 2012-03-28 | 2013-11-13 | 刘玉柱 | Traditional Chinese medicine for treating undifferentiated spondyloarthropathy |
| CN102836299A (en) * | 2012-09-28 | 2012-12-26 | 郑州中医骨伤病医院 | Kidney tonifying and pain relieving pill for treating ankylosing spondylitis |
| CN102847074A (en) * | 2012-09-28 | 2013-01-02 | 郑州中医骨伤病医院 | Blood stasis removing pill for treating ankylosing spondylitis |
| CN102836299B (en) * | 2012-09-28 | 2013-12-18 | 郑州中医骨伤病医院 | Kidney tonifying and pain relieving pill for treating ankylosing spondylitis |
| CN102847074B (en) * | 2012-09-28 | 2014-04-09 | 郑州中医骨伤病医院 | Blood stasis removing pill for treating ankylosing spondylitis |
| CN103272064A (en) * | 2013-06-17 | 2013-09-04 | 贵州鸿德中药开发有限公司 | Traditional Chinese medicine for treating rheumatoid arthritis and preparation method of traditional Chinese medicine |
| CN104644931A (en) * | 2015-01-29 | 2015-05-27 | 张爱文 | Traditional Chinese medicine for treating phlegm-dampness stagnation type knee joint wound synovitis |
| CN104644931B (en) * | 2015-01-29 | 2018-09-18 | 王金霞 | A kind of Chinese medicine for treating type of stagnation of phlegm-damp traumatic synovitis of knee joint |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1286495C (en) | 2006-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1907462A (en) | Traditional Chinese medicine composition for treating hepatitis and fatty liver | |
| CN1286495C (en) | Medicine for treating rheumatoid arthritis and ankylosing spondylitis and its preparation method | |
| CN1876074A (en) | A constipation-treating medicament and preparation method thereof | |
| CN1712054A (en) | Qinchuan Tongbi tablet | |
| CN100341540C (en) | Angelica root mistletoe granules and its preparation method | |
| CN101073660A (en) | Chinese-medicinal composition for treating chronic hepatitis B and its production | |
| CN1840160A (en) | Powder for resisting hyperosteogeny | |
| CN1168488C (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN1506090A (en) | Rheum emodi wall extract and medicine composition with the extract as active component | |
| CN1276767C (en) | Traditional Chinese medicine for treating non-alcoholic simple fatty liver and its preparation method | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN101032540A (en) | Medicine composition for curing arthritis and the preparing method and purpose thereof | |
| CN1947767A (en) | Medicine for treating and preventing infantile mental retardation, and its prepn. method | |
| CN1679887A (en) | Chinese medicine composition for treating hepatitis | |
| CN1799603A (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN1283492A (en) | Tibetan medicine for treating hepatism and its preparing process | |
| CN1049596C (en) | Medicine composite for curing arthritis | |
| CN1276758C (en) | Compound preparation of Chinese traditional medicine for curing chronic fatigue syndrome and its preparation method | |
| CN1709329A (en) | Composition for treating female algomenorrhea and its preparing method | |
| CN1286522C (en) | Medicine for treating gastric and duodenal ulcer | |
| CN1557446A (en) | Compound medicine for treating gout | |
| CN1850265A (en) | Chinese medicine for treating nephrosis Yang deficiency syndrome | |
| CN100337649C (en) | Medicine for treating rheumatic arthritis and its preparing method | |
| CN1850192A (en) | Medicine composition for treating cerebral embolism sequela and rheumatoid arthritis and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Yu Yan Document name: Notification of Passing Examination on Formalities |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200806 Address after: 130033 No. 2888 Sendai street, Changchun economic and Technological Development Zone, Jilin Patentee after: CHANGCHUN YINGPING PHARMACEUTICAL Co.,Ltd. Address before: 130033 No. 2888 Sendai street, Changchun economic and Technological Development Zone, Jilin Patentee before: Wu Yingping |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061129 |